MEN-2312
- Generic Name
- MEN-2312
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06638307
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath